Gerald Clarke | 11/27/2013
There have been some high profile cases of antibodies causing severe reactions, as well as posing a high risk to patients, these late stage failures are hugely costly. Is there a way to prevent or predict these immune reactions to biologics? We spoke to Harald Kropshofer Senior Personalized Healthcare Leader, Pharmaceutical Development F. Hoffman La Roche about his work on whole blood assays to assess cytokine response and t cell dependant responses and how these can be integrated into the drug...
To continue reading this story Click Here
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More